Comparative Pharmacology
Head-to-head clinical analysis: DESOXIMETASONE versus TOPICORT LP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESOXIMETASONE versus TOPICORT LP.
DESOXIMETASONE vs TOPICORT LP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desoximetasone is a potent corticosteroid that binds to glucocorticoid receptors, modulating gene expression and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis. This leads to anti-inflammatory, antipruritic, and vasoconstrictive effects.
Topicort LP (desoximetasone) is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to intracellular glucocorticoid receptors, leading to modulation of gene expression that suppresses inflammatory mediators such as prostaglandins, leukotrienes, and cytokines.
Apply a thin film to affected skin areas twice daily.
Apply a thin film to the affected skin areas twice daily. Route: topical. Frequency: twice daily.
None Documented
None Documented
Clinical Note
moderateDesoximetasone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Desoximetasone is combined with Gatifloxacin."
Clinical Note
moderateDesoximetasone + Rosoxacin
"The risk or severity of adverse effects can be increased when Desoximetasone is combined with Rosoxacin."
Clinical Note
moderateDesoximetasone + Levofloxacin
"The risk or severity of adverse effects can be increased when Desoximetasone is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life is approximately 1.5–2 hours. Due to its topical use, systemic half-life is less clinically relevant; however, prolonged use on large areas or under occlusion may lead to systemic accumulation.
Terminal elimination half-life is approximately 2-4 hours after topical application. This short half-life reflects rapid systemic clearance and minimal accumulation with once-daily dosing.
Primarily renal (urinary) as inactive metabolites, with less than 5% unchanged drug. Fecal excretion accounts for a minor fraction, primarily via bile.
Primarily renal (urinary excretion of metabolites and unchanged drug). Biliary/fecal elimination is minimal, accounting for <5% of the dose.
Category A/B
Category C
Topical Corticosteroid
Topical Corticosteroid
Desoximetasone + Trovafloxacin
"The risk or severity of adverse effects can be increased when Desoximetasone is combined with Trovafloxacin."